Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nan Jing, China Clinical Trials

A listing of Nan Jing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma

This phase I clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of BTK inhibitor BGB-3111 in Chinese patients with B-cell lymphoma, by conducting in two stages, the first stage being the safety assessment of dose, and the second stage being the dose expansion. Part I: Safety evaluation ...

Phase

0.0 miles

Learn More »

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Phase

0.0 miles

Learn More »

Safely and Efficacy of ClinOleic-based Lipid Parenteral Nutrition

Small studies suggest differences in efficacy and safety exist between olive oil-based and soybean oil-based parenteral nutrition regimens in hospitalized adult patients. A study in China suggested that olive oil-based parenteral nutrition provided effective nutrition, was well tolerated, was associated with fewer infections and conferred greater ease-of-use than soybean oil-based ...

Phase

0.0 miles

Learn More »

Rekovelle PK Trial in Chinese Women

FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating hormone (rhFSH) under development by Ferring Pharmaceuticals for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. In previous trials ...

Phase

0.0 miles

Learn More »

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

This is an open, single-arm,multicenter 2 phase clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD19 positive lymphoma. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the following sequential phases: part A (screening, leukapheresis, cell ...

Phase

0.11 miles

Learn More »

Study of Endostar Subcutaneous Injection in NSCLC

This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.

Phase

0.11 miles

Learn More »

Safety Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered SH-1028 tablets. The overall study design is shown in the flow chart below, which consists of 2 phases: dose escalation and dose expansion cohort.

Phase

0.11 miles

Learn More »

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Phase

0.11 miles

Learn More »

Injectable Collagen Scaffold Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes

The intent of this clinical study is to answer the questions: 1) is the proposed treatment feasible; 2) is treatment effective in improving the disease pathology of patients with diagnosed diabetic erectile dysfunction.

Phase

0.68 miles

Learn More »

Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a JNJ-61186372 Monotherapy and Combination Dose Escalations and Part 2 JNJ-61186372 Monotherapy and Combination Dose Expansions. In Part 1, participants with evaluable NSCLC ...

Phase

0.94 miles

Learn More »